Trial Profile

A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared With Placebo in Healthy Participants

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART-5803 (Primary)
Indications Anti-N-methyl-D-aspartate-receptor-encephalitis; Autoimmune disorders
Focus Adverse reactions; First in man
Sponsors Arialys Therapeutics

11 Jul 2025 Status changed from recruiting to active, no longer recruiting.
17 Jun 2025 According to an Arialys Therapeutics media release, The company expects to share initial clinical data in the second half of 2025.
26 Feb 2025 According to an Arialys Therapeutics media release, study is being conducted in collaboration with Nucleus Network inMelbourne, Australia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com